NAS:FIXX (USA) Also trade in: Germany UK

Homology Medicines Inc

$ 18.35 -1.24 (-6.33%)
Volume: 214,450 Avg Vol (1m): 290,289
Market Cap $: 815.61 Mil Enterprise Value $: 627.62 Mil
P/E (TTM): 0.00 P/B: 3.95
Earnings Power Value 0
Net Current Asset Value 3.52
Tangible Book 4.66
Projected FCF 0
Median P/S Value 3.74
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
1Y (-%)

Financial Strength : 9/10

GuruFocus Financial Strength Rank measures how strong a company's financial situation is . It is based on these factors
1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
Current vs industry vs history
Cash-to-Debt No Debt
Cash-To-Debt ranked higher than
59.00% of 1078 companies
in the Biotechnology industry.
Industry Max: 20856.43, Med: 64.02, Min: 0.01
FIXX: No Debt
Ranked among companies with meaningful Cash-To-Debt only.
N/A
Equity-to-Asset 0.75
Equity-to-Asset ranked lower than
100.00% of 763 companies
in the Biotechnology industry.
Industry Max: 3.47, Med: 0.69, Min: -9.46
FIXX: 0.75
Ranked among companies with meaningful Equity-to-Asset only.
Equity-to-Asset range over the past 10 years
Min: -0.38, Med: 0.75, Max: 0.84
Current: 0.75
-0.38
0.84
Interest Coverage No Debt
Interest Coverage ranked lower than
52.00% of 500 companies
in the Biotechnology industry.
Industry Max: 22756408, Med: 10000, Min: 0.12
FIXX: No Debt
Ranked among companies with meaningful Interest Coverage only.
N/A
Altman Z-Score 8.08
DISTRESS
GREY
SAFE

Profitability & Growth : 2/10

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
Current vs industry vs history
Operating Margin % -2418.02
Operating Margin ranked lower than
100.00% of 792 companies
in the Biotechnology industry.
Industry Max: 46829238.82, Med: -113.97, Min: -1969600
FIXX: -2418.02
Ranked among companies with meaningful Operating Margin only.
Operating Margin range over the past 10 years
Min: -2418.02, Med: -1671.12, Max: -1671.12
Current: -2418.02
-2418.02
-1671.12
Net Margin % -2253.77
Net Margin ranked lower than
100.00% of 792 companies
in the Biotechnology industry.
Industry Max: 49899604.52, Med: -111.91, Min: -2150400
FIXX: -2253.77
Ranked among companies with meaningful Net Margin only.
Net Margin range over the past 10 years
Min: -2253.77, Med: -1553.07, Max: -1553.07
Current: -2253.77
-2253.77
-1553.07
ROE % -46.47
ROE ranked lower than
61.58% of 989 companies
in the Biotechnology industry.
Industry Max: 326.78, Med: -42.82, Min: -100794.12
FIXX: -46.47
Ranked among companies with meaningful ROE only.
ROE range over the past 10 years
Min: -73.7, Med: -73.7, Max: -46.47
Current: -46.47
-73.7
-46.47
ROA % -30.41
ROA ranked lower than
54.15% of 1084 companies
in the Biotechnology industry.
Industry Max: 224.74, Med: -34.77, Min: -3751.92
FIXX: -30.41
Ranked among companies with meaningful ROA only.
ROA range over the past 10 years
Min: -56.59, Med: -39.53, Max: -28.85
Current: -30.41
-56.59
-28.85
ROC (Joel Greenblatt) % -349.96
ROC (Joel Greenblatt) ranked lower than
60.33% of 1036 companies
in the Biotechnology industry.
Industry Max: 641137.84, Med: -521.46, Min: -3427023.81
FIXX: -349.96
Ranked among companies with meaningful ROC (Joel Greenblatt) only.
ROC (Joel Greenblatt) range over the past 10 years
Min: -1160.74, Med: -511.25, Max: -317.41
Current: -349.96
-1160.74
-317.41

» FIXX's 30-Y Financials

Financials (Next Earnings Date: 2019-08-13)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:FIXX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare
Traded in other countries 35H.Germany 0T6G.UK
Address 45 Wiggins Avenue, Bedford, MA, USA, 01730
Homology Medicines is an US based genetic medicines company. It is based on groundbreaking science that harnesses the naturally occurring process of homologous recombination. It is dedicated towards translating proprietary, cutting-edge gene editing and gene therapy technology into cures for patients with rare diseases.

Ratios

Current vs industry vs history
PB Ratio 3.95
PB Ratio ranked higher than
61.85% of 962 companies
in the Biotechnology industry.
Industry Max: 2236, Med: 4.1, Min: 0.05
FIXX: 3.95
Ranked among companies with meaningful PB Ratio only.
PB Ratio range over the past 10 years
Min: 2.55, Med: 3.95, Max: 6.51
Current: 3.95
2.55
6.51
PS Ratio 215.87
PS Ratio ranked lower than
100.00% of 726 companies
in the Biotechnology industry.
Industry Max: 113071.43, Med: 9999, Min: 0.01
FIXX: 215.87
Ranked among companies with meaningful PS Ratio only.
PS Ratio range over the past 10 years
Min: 32.5, Med: 43.96, Max: 356.94
Current: 215.87
32.5
356.94
EV-to-EBIT -8.30
EV-to-EBIT ranked lower than
100.00% of 261 companies
in the Biotechnology industry.
Industry Max: 4391.42, Med: 22.17, Min: 0.02
FIXX: -8.3
Ranked among companies with meaningful EV-to-EBIT only.
EV-to-EBIT range over the past 10 years
Min: -12.6, Med: -9.5, Max: 2
Current: -8.3
-12.6
2
EV-to-EBITDA -8.56
EV-to-EBITDA ranked lower than
100.00% of 281 companies
in the Biotechnology industry.
Industry Max: 28816.43, Med: 18.08, Min: 0.02
FIXX: -8.56
Ranked among companies with meaningful EV-to-EBITDA only.
EV-to-EBITDA range over the past 10 years
Min: -12.9, Med: -9.7, Max: 2.1
Current: -8.56
-12.9
2.1
EV-to-Revenue 200.52
EV-to-Revenue ranked lower than
100.00% of 771 companies
in the Biotechnology industry.
Industry Max: 118933, Med: 13.69, Min: 0.05
FIXX: 200.52
Ranked among companies with meaningful EV-to-Revenue only.
EV-to-Revenue range over the past 10 years
Min: -63.4, Med: 174.7, Max: 302.3
Current: 200.52
-63.4
302.3
Current Ratio 10.80
Current Ratio ranked higher than
86.31% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.46, Min: 0.01
FIXX: 10.8
Ranked among companies with meaningful Current Ratio only.
Current Ratio range over the past 10 years
Min: 1.88, Med: 12.75, Max: 24.05
Current: 10.8
1.88
24.05
Quick Ratio 10.80
Quick Ratio ranked higher than
86.59% of 1074 companies
in the Biotechnology industry.
Industry Max: 3987.61, Med: 4.18, Min: 0.01
FIXX: 10.8
Ranked among companies with meaningful Quick Ratio only.
Quick Ratio range over the past 10 years
Min: 1.88, Med: 12.75, Max: 24.05
Current: 10.8
1.88
24.05

Dividend & Buy Back

Current vs industry vs history

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 3.94
Price-to-Tangible-Book ranked higher than
69.35% of 894 companies
in the Biotechnology industry.
Industry Max: 800, Med: 5.32, Min: 0.05
FIXX: 3.94
Ranked among companies with meaningful Price-to-Tangible-Book only.
Price-to-Tangible-Book range over the past 10 years
Min: 3.35, Med: 4.12, Max: 5.95
Current: 3.94
3.35
5.95
Price-to-Median-PS-Value 4.91
Price-to-Median-PS-Value ranked lower than
100.00% of 678 companies
in the Biotechnology industry.
Industry Max: 126.94, Med: 0.92, Min: 0.01
FIXX: 4.91
Ranked among companies with meaningful Price-to-Median-PS-Value only.
Price-to-Median-PS-Value range over the past 10 years
Min: 0.94, Med: 0.97, Max: 7.41
Current: 4.91
0.94
7.41
Earnings Yield (Joel Greenblatt) % -12.07
Earnings Yield (Greenblatt) ranked higher than
53.38% of 1081 companies
in the Biotechnology industry.
Industry Max: 5000, Med: -7.73, Min: -10000
FIXX: -12.07
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
Earnings Yield (Greenblatt) range over the past 10 years
Min: -15, Med: -9.8, Max: 56.7
Current: -12.07
-15
56.7

More Statistics

Revenue (TTM) (Mil) $ 3.13
EPS (TTM) $ -1.91
Beta 0
Volatility % 73.05
52-Week Range $ 15.07 - 31.8
Shares Outstanding (Mil) 44.45

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N